Polyarticular JIA in Children: What to Do When Initial DMARD Therapy Has Not Achieved Low Disease Activity
Clinical Scenario
This protocol addresses children under 16 years with juvenile idiopathic arthritis (JIA) and non-systemic polyarthritis — five or more joints ever involved — without systemic arthritis or sacroiliitis. JIA encompasses a heterogeneous group of inflammatory arthritides of unknown cause beginning before age 16, persisting at least 6 weeks, after other known causes of synovitis have been excluded.
Escalation Trigger — Why This Step Is Reached
This protocol is entered when first-line therapy — Methotrexate monotherapy as initial DMARD, with adjunct NSAIDs, intraarticular triamcinolone hexacetonide, bridging glucocorticoids as appropriate, and physical or occupational therapy — has not achieved low disease activity (cJADAS-10 ≤2.5) by 3 months. Persistent moderate or high disease activity despite that initial regimen is the condition that triggers the next step.
Treatment Goal
The clinical target remains low disease activity (cJADAS-10 ≤2.5), with therapeutic escalation recommended to achieve it.
Approach — Partial Overview
When initial DMARD monotherapy has not achieved the disease-activity target, evidence-based guidance supports adding a biologic agent in combination with the existing DMARD, rather than switching to a different DMARD alone. Which biologic, and whether combination is conditionally or strongly recommended, varies by agent — the full structured regimen is in the complete protocol.
References
DOI: 10.1002/acr.23870
- This group includes children with JIA and polyarthritis (≥5 joints ever involved) and may include children from different ILAR JIA categories but excludes children with systemic arthritis or sacroiliitis.
- The term juvenile idiopathic arthritis (JIA) defines a heterogeneous collection of inflammatory arthritides of unknown etiology with onset prior to age 16 years and a minimum duration of 6 weeks, following the exclusion of other known causes of synovitis.
- In patients with JIA and polyarthritis and moderate or high disease activity despite DMARD monotherapy, adding a biologic to the original DMARD is conditionally recommended over changing to a second DMARD.
- In patients with JIA and polyarthritis and moderate or high disease activity receiving DMARD monotherapy, adding a biologic is conditionally recommended over changing to triple DMARD therapy.
- In children and adolescents with JIA and polyarthritis initiating treatment with a biologic (etanercept, adalimumab, golimumab, abatacept, or tocilizumab), combination therapy with a DMARD is conditionally recommended over biologic monotherapy.
- Combination therapy with a DMARD is strongly recommended for infliximab.
- Good disease control, with therapeutic escalation to achieve low disease activity, was recommended.
View source ↗